This report describes and explains the dengue vaccine market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global dengue vaccine market reached a value of nearly $408.19 million in 2024, having grown at a compound annual growth rate (CAGR) of 174.86% since 2019. The market is expected to grow from $408.19 million in 2024 to $987.42 million in 2029 at a rate of 19.32%. The market is then expected to grow at a CAGR of 16.77% from 2029 and reach $2.14 billion in 2034.
Growth in the historic period resulted from the rising dengue incidence, expansion of vaccination programs, public awareness campaigns and increasing healthcare infrastructure. Factors that negatively affected growth in the historic period was limited vaccine availability.
Going forward, the increasing healthcare expenditure, strong economic growth in emerging markets, favorable government initiatives and increasing number of population will drive the growth. Factor that could hinder the growth of the dengue vaccine market in the future include economic constraints.
The global dengue vaccine market is highly concentrated, with few players operating in the market. The top ten competitors in the market made up to 100% of the total market in 2023. Takeda Pharmaceutical Company Limited was the largest competitor with a 90.85% share of the market, followed by Sanofi SA with 9.15%.
South America was the largest region in the dengue vaccine market, accounting for 40.79% or $166.49 million of the total in 2024. It was followed by Asia Pacific, North America and then the other regions. Going forward, the fastest-growing regions in the dengue vaccine market will be Asia Pacific and Middle East where growth will be at CAGRs of 20.70% and 20.33% respectively. These will be followed by South America and Eastern Europe where the markets are expected to grow at CAGRs of 18.97% and 17.00% respectively.
The dengue vaccine market is segmented by type into live attenuated vaccine, inactivated vaccine, subunit vaccine and nucleic acid-based vaccine. The live attenuated vaccine market was the largest segment of the dengue vaccine market segmented by type, accounting for 100.00% or $408.19 million of the total in 2024. Going forward, the live attenuated vaccine segment is expected to be the fastest growing segment in the dengue vaccine market segmented by type, at a CAGR of 18.54% during 2024-2029.
The dengue vaccine market is segmented by route of administration into oral, parenteral and other routes of administration. The parenteral market was the largest segment of the dengue vaccine market segmented by route of administration, accounting for 100.00% or $408.19 million of the total in 2024. Going forward, the parenteral segment is expected to be the fastest growing segment in the dengue vaccine market segmented by route of administration, at a CAGR of 18.32% during 2024-2029.
The dengue vaccine market is segmented by end user into hospitals, clinics, government institutes, non-governmental organizations and other end-users. The hospitals market was the largest segment of the dengue vaccine market segmented by end user, accounting for 64.86% or $264.76 million of the total in 2024. Going forward, the government institutes segment is expected to be the fastest growing segment in the dengue vaccine market segmented by end user, at a CAGR of 24.24% during 2024-2029.
The top opportunities in the dengue vaccine market segmented by type will arise in the live attenuated vaccine segment, which will gain $547.04 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by route of administration will arise in the parenteral segment, which will gain $538.24 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by end user will arise in the hospitals segment, which will gain $353.32 million of global annual sales by 2029. The dengue vaccine market size will gain the most in Brazil at $123.96 million.
Market-trend-based strategies for the dengue vaccine market include focus on prioritizing the development of innovative diagnostic kits to facilitate early detection, improve diagnostic accuracy and enable timely treatment of dengue infections, focus on strategic investments to expand their product portfolios, enhance vaccine efficacy and improve global access and focus on embracing strategic partnerships to drive the development of advanced vaccines.
Player-adopted strategies in the dengue vaccine market include focus on expanding manufacturing capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the dengue vaccine companies to focus on developing innovative diagnostic kits for dengue, focus on strategic investments for vaccine development, focus on nucleic acid-based vaccines for dengue, focus on oral vaccines for dengue prevention, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for vaccine development, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, focus on government institutes for vaccine development and focus on targeting growing populations for vaccine strategies.
The global dengue vaccine market reached a value of nearly $408.19 million in 2024, having grown at a compound annual growth rate (CAGR) of 174.86% since 2019. The market is expected to grow from $408.19 million in 2024 to $987.42 million in 2029 at a rate of 19.32%. The market is then expected to grow at a CAGR of 16.77% from 2029 and reach $2.14 billion in 2034.
Growth in the historic period resulted from the rising dengue incidence, expansion of vaccination programs, public awareness campaigns and increasing healthcare infrastructure. Factors that negatively affected growth in the historic period was limited vaccine availability.
Going forward, the increasing healthcare expenditure, strong economic growth in emerging markets, favorable government initiatives and increasing number of population will drive the growth. Factor that could hinder the growth of the dengue vaccine market in the future include economic constraints.
The global dengue vaccine market is highly concentrated, with few players operating in the market. The top ten competitors in the market made up to 100% of the total market in 2023. Takeda Pharmaceutical Company Limited was the largest competitor with a 90.85% share of the market, followed by Sanofi SA with 9.15%.
South America was the largest region in the dengue vaccine market, accounting for 40.79% or $166.49 million of the total in 2024. It was followed by Asia Pacific, North America and then the other regions. Going forward, the fastest-growing regions in the dengue vaccine market will be Asia Pacific and Middle East where growth will be at CAGRs of 20.70% and 20.33% respectively. These will be followed by South America and Eastern Europe where the markets are expected to grow at CAGRs of 18.97% and 17.00% respectively.
The dengue vaccine market is segmented by type into live attenuated vaccine, inactivated vaccine, subunit vaccine and nucleic acid-based vaccine. The live attenuated vaccine market was the largest segment of the dengue vaccine market segmented by type, accounting for 100.00% or $408.19 million of the total in 2024. Going forward, the live attenuated vaccine segment is expected to be the fastest growing segment in the dengue vaccine market segmented by type, at a CAGR of 18.54% during 2024-2029.
The dengue vaccine market is segmented by route of administration into oral, parenteral and other routes of administration. The parenteral market was the largest segment of the dengue vaccine market segmented by route of administration, accounting for 100.00% or $408.19 million of the total in 2024. Going forward, the parenteral segment is expected to be the fastest growing segment in the dengue vaccine market segmented by route of administration, at a CAGR of 18.32% during 2024-2029.
The dengue vaccine market is segmented by end user into hospitals, clinics, government institutes, non-governmental organizations and other end-users. The hospitals market was the largest segment of the dengue vaccine market segmented by end user, accounting for 64.86% or $264.76 million of the total in 2024. Going forward, the government institutes segment is expected to be the fastest growing segment in the dengue vaccine market segmented by end user, at a CAGR of 24.24% during 2024-2029.
The top opportunities in the dengue vaccine market segmented by type will arise in the live attenuated vaccine segment, which will gain $547.04 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by route of administration will arise in the parenteral segment, which will gain $538.24 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by end user will arise in the hospitals segment, which will gain $353.32 million of global annual sales by 2029. The dengue vaccine market size will gain the most in Brazil at $123.96 million.
Market-trend-based strategies for the dengue vaccine market include focus on prioritizing the development of innovative diagnostic kits to facilitate early detection, improve diagnostic accuracy and enable timely treatment of dengue infections, focus on strategic investments to expand their product portfolios, enhance vaccine efficacy and improve global access and focus on embracing strategic partnerships to drive the development of advanced vaccines.
Player-adopted strategies in the dengue vaccine market include focus on expanding manufacturing capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the dengue vaccine companies to focus on developing innovative diagnostic kits for dengue, focus on strategic investments for vaccine development, focus on nucleic acid-based vaccines for dengue, focus on oral vaccines for dengue prevention, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for vaccine development, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, focus on government institutes for vaccine development and focus on targeting growing populations for vaccine strategies.
Major Market Trends
- Advancements in Diagnostic Kits For Early Detection of Dengue Infections
- Investment in Novel Dengue Treatment Solutions To Address Rising Global Incidence
- Strategic Partnerships Driving Innovation in the Dengue Vaccine Market
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Dengue Vaccine Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Dengue Vaccine Market Segmentation
11 Dengue Vaccine Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
20 Other Major and Innovative Companies
23 Opportunities and Strategies
24 Dengue Vaccine Market, Conclusions and Recommendations
25 Appendix
Executive Summary
Dengue Vaccine Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global dengue vaccine market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for dengue vaccine? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The dengue vaccine market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider dengue vaccine market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by route of administration and by end user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the dengue vaccine market.
- Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by route of administration and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations - This section includes recommendations for dengue vaccine market providers in terms of product/service offerings geographic expansion, marketing strategies and target groups next five years.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Type: Live Attenuated Vaccine; Inactivated Vaccine; Subunit Vaccine; Nucleic Acid-Based Vaccine2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
3) By End User: Hospitals; Clinics; Government Institutes; Non-Governmental Organizations; Other End-Users
Key Companies Mentioned: Takeda Pharmaceutical Company Limited; Sanofi SA; GlaxoSmithKline plc; Merck & Co. Inc.; Panacea Biotec Ltd.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; dengue vaccine indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
The major companies featured in this Dengue Vaccine market report include:- Takeda Pharmaceutical Company Limited
- Sanofi SA
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Panacea Biotec Ltd.
- Codagenix Inc.
- Serum Institute of India Pvt. Ltd.
- Inovio Pharmaceuticals Inc.
- Novavax Inc.
- Medigen Vaccine Biologics Corporation
- Bharat Biotech Ltd.
- Biological E. Limited
- Sun Pharmaceutical Industries Ltd.
- BioNet-Asia Co. Ltd.
- Zhejiang Tianyuan Bio-Pharmaceutical
- Walvax Biotechnology Co., Ltd.
- Bavarian Nordic
- Pfizer Inc., Vaxess Technologies
- Viatris Inc
- Emergent BioSolutions Inc.
- Altimmune, Inc.
- Baxter International Inc
- Moderna, Inc.
- Valneva SE
- AstraZeneca
- Johnson & Johnson
- Dynavax Technologies Corporation
- Pfizer Inc.
- BioNTech SE
- Moderna Inc., Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Vabiotech
- CSL Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 294 |
| Published | March 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 408.2 Million |
| Forecasted Market Value ( USD | $ 2140 Million |
| Compound Annual Growth Rate | 18.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 35 |
